Avalyn Pharma Inc., a clinical-stage biopharmaceutical company pioneering inhaled therapies for treating pulmonary fibrosis, is set to begin trading on the Nasdaq Global Select Market under the ticker symbol "AVLN" on April 30, 2026.
The company has priced its upsized initial public offering of 16.67 million shares of its common stock at $18.00 per share. The offering is scheduled to close on May 1, 2026, and gross proceeds to Avalyn are expected to be $300 million.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.